Merck and the University of Cape Town to Develop a Drug Discovery Platform for Malaria
Merck announced that a research agreement has been signed with the University of Cape Town (UCT) South Africa to co-develop a new R&D platform aimed at identifying new lead programs for potential treatments against malaria, with the potential to expand it to other tropical diseases.
Combining Merck’s R&D expertise and the drug discovery capabilities of the UCT Drug Discovery and Development Centre, H3D, the collaboration will conduct drug discovery research with the goal of developing anti-malarial drug candidates using Merck’s compound library.
“This strategic collaboration shows the commitment of Merck to provide access to medicines for underserved populations, while creating a potential long-term alliance for generating new drugs to treat infectious diseases,” said Beatrice Greco, Head of Malaria and Diagnostics - Global Health R&D, within the biopharmaceutical business of Merck.

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.